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Abstract 
 
Aims: Detection/Quantitation of RNA viruses is mostly done by reverse transcriptase 
(RT)-(q)PCR, but it does not distinguish between infectious and non-infectious 
viruses. Our aim was to test, how different pretreatments before RT-qPCR could 
eliminate positivity originated from external nucleic acids or genomes of damaged 
particles.  
Methods and Results: Heat-inactivated (80 °C for 10 min) rotavirus Wa strain and 
fecal samples containing rotavirus or norovirus were treated with PMA/PMAxx, 
benzonase or crude extract RNase prior to RT-qPCR. PMA/PMAxx pretreatments 
were not consistently efficient for RV, although they seemed to work to some extent 
for heat-inactivated norovirus. Benzonase and RNase provided consistently 2.2 – 2.8 
log10 reductions in the titer of fecal rotavirus. 
Conclusions: All pretreatments need to be further validated for each virus 
separately, taking into account sample matrix and inactivation conditions. Although 
none of the pretreatments could completely render inactivated viruses undetectable, 
RNase worked most consistently for both rota- and norovirus.  
Significance and Impact of the Study: This study sheds light on capacity of the 
most common pre-RT-qPCR treatments to eliminate damaged, non-infectious 
rotaviruses and noroviruses after thermal treatment. To our knowledge, this is the 
first time, when benzonase has been used in this context. 
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Introduction 
Human rotavirus (RV) and norovirus (NoV) are the most important viruses causing 
gastrointestinal illness worldwide. Despite effective vaccines have greatly decreased 
RV mortality, ≥ 200 000 children still die annually because of RV infection (Tate and 
Parashar 2014); Tate et al. 2016). Majority of these deaths occur in the developing 
countries, where contaminated drinking water is an important source of infection. For 
NoV, it has been estimated, that annual morbidity was 677 billion in 2010, and it 
caused over 200 000 deaths (Pires et al. 2015). 
RV has a segmented double-stranded RNA genome that is shielded by an inner core 
(core protein VP2), an inner capsid (VP6) and an outer capsid (protein VP7 and a 
spike protein VP4; Azevedo et al. 2014). NoV is quite different from RV, since it has 
a non-segmented, single-stranded RNA genome, and its virion is formed of a major 
capsid protein VP1 and a minor structural protein VP2 (Tan and Jiang, 2014). 
Capsid damage with subsequent damage of the genome appears to be the most 
common reason for rendering viruses non-infectious (Cliver 2009). An undamaged 
capsid is crucial for viruses for entering the host cell, but it also protects the viral 
genome, e.g. from nucleases. Another important mechanism for rendering viruses 
non-infectious is a direct damage to the genome, which can happen, for example, 
when the virus is subjected to ultraviolet light (UV).  
Infected persons shed immense amounts (up to 1010) of these viruses into feces, 
which is further discharged to sewage. Survival of the viruses in surface or ground 
water depends on the virus in question; rotavirus and norovirus can survive 
infectious for weeks to months (Bae and Schwab 2007; Espinosa et al. 2008). 
Nowadays, the detection of viruses is usually made by (reverse-transcription)-
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compared to cell culture methods, that it does not provide any information on 
whether the genome equivalents are associated to infectious viral particles or not. 
The infectivity of the detected viral particles is, however, important to know when 
assessing the risk of fecally contaminated water to consumers.    
The abilities of different enzymatic pretreatments for removing damaged, non-
infectious viral particles from samples containing viruses prior to RT-PCR have been 
tested widely (Nuanualsuwan and Cliver 2002; Lamhoujeb et al. 2008; Topping et al. 
2009; Diez-Valcarce et al. 2011; Li et al. 2012; Escudero-Abarca et al. 2014; 
Rönnqvist et al. 2014; Manuel et al. 2017; Monteiro and Santos 2017).  Proteinases 
have been used to break down partially damaged viral capsids, and RNases to 
digest free nucleic acids from damaged viral particles. In addition to enzymatic 
treatments, also chemicals, such as intercalating dyes propidium monoazide (PMA) 
and ethidium monoazide (EMA), as well as surfactants, have been used to get the 
same end result. (Parshionikar et al. 2010; Kim et al. 2012; Sánchez et al. 2012; 
Coudray-Meunier et al. 2013; Elizaquivel et al. 2014; Escudero-Abarca et al. 2014; 
Karim et al. 2015; Leifels et al. 2015; Monteiro and Santos 2017). PMA acts by 
covalently binding to nucleic acids upon photoactivation and prevents amplification, 
while surfactants may help PMA to penetrate mildly damaged viral capsids 
(Coudray-Meunier et al. 2013). Other methods, such as various binding assays and 
large fragment amplification, have been applied for discriminating intact particles or 
genomes from the damaged ones (Li et al. 2011; Ceuppens et al. 2014). Based on 
the literature, it seems that the effect of a pretreatment is highly dependable on the 
virus in question, sample matrix and of the process that has been used for viral 
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The purpose of this study was to evaluate the abilities of PMA, PMAxx (a dye 
structurally related to PMA, but with different chemical properties), benzonase and 
RNase pretreatments to reduce the quantified RT-qPCR genome copy (gc) numbers 
of thermally-inactivated RV and NoV. Benzonase is a nuclease that degrades both 
single- and double-stranded RNA and DNA (Miller et al. 1994). To our knowledge, it 
has not been used in this context before. As model viruses, we used cell culture-
propagated RV strain Wa, and two fecal samples containing either RV or NoV.  
 
Materials and methods 
Preparation of the virus stocks  
MA104 cells were grown in Eagle’s Minimum Essential Medium (EMEM; Sigma-
Aldrich Co., Saint Louis, MO, USA), containing 10% heat-inactivated foetal bovine 
serum (FBS; Thermo Fischer Scientific Inc., Waltham, MA, USA), 10 mM HEPES (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid) solution (Sigma-Aldrich Co.) and 1 
% glutamine-penicillin-streptomycin (Sigma-Aldrich Co.) The cells were incubated at 
37°C in an atmosphere containing 5% CO2 until they reached 80% confluency. The 
cells were infected with rotavirus strain Wa G1P[8] (kindly gifted by Professor 
Lennart Svensson at the Linköping University, Linköping, Sweden) according to the 
protocol described by Arnold et al. (2009). Incubation at 37°C was continued for 2 – 
3 days, and the cells were checked for cytopathic effect (CPE). The viruses were 
released by freeze-thawing and centrifuged at 4,500 g for 10 min. The supernatant 
was divided into aliquots and stored at -70°C. Infectivity of the virus stock was 
measured by the 50% tissue culture infectious dose method (TCID50/ml
-1). In brief, 
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were infected with 200 µl of each 10-fold serial dilution of trypsin-activated rotavirus 
Wa. The Wa stock contained approximately 3 x 105 TCID50/ml
-1.    
Also, two 10% human (anonymous) fecal suspensions, one containing a high 
number of RV G1P[8] particles by electron microscopy (EM; from here on referred as 
F_RV), and the other containing a high genome load of NoV GI.Pb-GI.6 (from here 
on referred as F_NoV; GenBank accession no. for ORF1 identical to KT943508 and 
for ORF2 to KT943509; Oristo et al. 2017), were prepared in sterile 1 x phosphate 
buffered saline (PBS; Sigma-Aldrich Co.). The fecal suspensions were thoroughly 
mixed by vortexing, and incubated at 6°C for 24 – 72 hours, before clarification by 
centrifugation at 10,000 g for 10 min. The supernatants were stored in aliquots at -
70°C. 
To obtain optimal concentrations for the RT-qPCR experiments, the Wa stock and 
the fecal suspensions F_RV and F_NoV were further diluted in PBS. The working 
dilutions were freshly prepared for each experiment. The RT-qPCR concentrations of 
these diluted Wa, F_RV and F_NoV aliquots were determined to be 1.7 x 108 (gc) 
ml-1 (corresponding to approximately 3 x 103 TCID50 ml
-1, 7.6 x 108 gc ml-1, and 3.2 x 
108 gc ml-1, respectively, by the RT-qPCR methods described below). The 
corresponding concentrations in 1 µl of extracted RNA were 2.8 x 105 gc for Wa, 1.3 
106 for F_RV, and 5.3 x 105 for F_NoV. 
 
Thermal inactivation of the model viruses 
To determine the time for complete inactivation of Wa, virus aliquots were thermally 
treated at 80 °C for 1 – 30 min in a dry bath, and the TCID50 concentration was 
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for 10 min) samples containing F_RV particles were examined by EM. Viruses were 
identified on grids negatively stained with 1% potassium phosphotungstate, pH 6.5.  
For PMA and nuclease treatment studies, we inactivated the viral aliquots in a dry 
bath set at 80 °C for 10 min, after which they were placed on ice immediately. Virus 
samples without and with heat-inactivation are referred as “infectious” and “heat-
inactivated” viruses, respectively. 
 
PMA/PMAxx pretreatments   
Based on our preliminary tests, we decided to use a final concentration of 100 µmol l-
1 PMA/PMAxx (Biotium, Hayward, CA, USA). PMA/PMAxx in sterile H2O at 2mM was 
stored in aliquots at -20°C, protected from light. As a first step, we tested the ability 
of PMA/PMAxx to bind to free nucleic acids by treating 100 µl aliquots of extracted 
Wa RNA with µmol l-1 of PMA/PMAxx. PMA/PMAxx treated samples underwent 
incubation in the dark for 60 min at 6°C, and photoactivation (performed with 
Biotium-Lite LED Photolysis device (Biotium) for 15 min at room temperature.  
Half of the PMA/PMAxx-treated RNA samples were further purified with the QiaQuick 
PCR Purification kit (QIAGEN), according the manufacturer’s instructions, and half 
was not purified further. Adequate controls treated with µmol l-1 PMA/PMAxx, and 
either subjected to photoactivation or not, were included in the experiments. 
PMA/PMAxx treatment for infectious or heat-inactivated Wa, F_RV and F_NoV 
samples was done accordingly by adding the dye into 100 µl aliquots of virus. Virus 
containing samples were frozen (-20°C) until subjected to RNA extraction. All 
experiments with the infectious and heat-inactivated viruses were done at least 
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Nuclease pretreatment 
We first wanted to ensure that benzonase (Sigma-Aldrich, St. Louis, MO, USA) 
degrades nucleic acids efficiently. Benzonase treatment was otherwise performed 
similarly to PMA treatment, but with 100 U of benzonase per sample, and incubation 
at 37°C for 1 h. Treatment of the 100 µl aliquots of infectious and heat-inactivated 
Wa, F_RV and F_NoV samples was performed similarly prior to RNA extraction. 
Pretreatment of the viral aliquots with a crude mixture of RNases from bovine 
pancreas (Roche Diagnostics, Mannheim, Germany) was performed as described by 
Rönnqvist et al. (2014), with minor modifications. Briefly, 4 U of RNase was added 
per 100 µl of diluted Wa, F_RV or F_NoV aliquots, and the mixtures were then 
incubated for 30 min at 37 °C. 80 U of RiboLock RNase inhibitor (Promega, Madison, 
USA) was added after the incubation to stop the reaction.   
The control samples were always treated the same way as the nuclease-treated 
samples, but without addition of nuclease. We also tested, if the heating of F_NoV 
samples at 37 °C for 30 or 60 min would decrease the viral titer in comparison with 
the samples kept at 6°C (PMA treatment) for the similar amount of time. All 
experiments with the infectious and heat-inactivated viruses were done at least 
thrice, except for the infectious Wa samples treated with benzonase, which was 
done twice.  
 
RNA extraction and detection of Wa and F_RV by RT-qPCR 
RNA of the Wa and F_RV samples was extracted with the E.Z.N.A Viral RNA kit 
(Omega Bio-tek Inc., Georgia, USA). The extractions were performed according to 
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to 140 µl with PBS prior to the extraction, and the samples were eluted in 60 µl using 
the elution buffer provided by the extraction kit’s manufacturer. The RNA samples 
were stored at -20°C until further use. 
Expand reverse-transcriptase enzyme (25 U) (Roche Diagnostics GmbH, Mannheim, 
Germany) was used to produce cDNA of RV RNA. The 10µl-mix was otherwise 
prepared as described by Kantala et al. (2009), but with 1.0 µmol l-1 of rotavirus-
specific reverse primer Z_RV_R (Table 1) and 3 µl of denatured (97°C, 5 min) RV 
RNA. The RT was performed at 42°C for 60 min. One PCR reaction mix (25 µl) 
consisted of 10 µl 2x Rotor-Gene SYBR Green PCR Master Mix (QIAGEN), 1.0 µmol 
l-1 of each reverse (Z_RV_R) and forward (Z_RV_F) primers (Table 1), H2O, and 5 µl 
of template cDNA. Amplification was performed with the Rotor-Gene Q thermal 
cycler (QIAGEN) in the following conditions: initial activation at 95°C for 5 min, 
followed by 45 cycles of 95 °C for 5 s and 60 °C for 10 s.  
 
RNA extraction and detection of F_NoV by RT-qPCR  
RNA of all the F_NoV samples was extracted with the E.Z.N.A Viral RNA kit (Omega 
Bio-tek Inc.), as explained above. Detection of F_NoV by RT-qPCR was performed 
in 20 µl-volume with the QuantiTect Probe RT-PCR kit (QIAGEN), 0.9 µmol l-1 of 
NVLCR1 reverse primer, 0.9 µmol l-1 of QNIF4 forward primer, and 0.3 µmol l-1 of 
TM9 probe (Table 1). Amplification was performed with the Rotor-Gene Q (QIAGEN) 
thermal cycler in the following conditions: RT at 55°C for 60 min and initial activation 
at 95°C for 15 min, followed by 45 cycles of 95 °C for 15 s, 60 °C for 60 s and 65 °C 
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Digital droplet PCR and standard curves 
Digital droplet PCR (ddPCR) was used for determining the genome copy numbers of 
the standard samples (Wa and F_NoV). Detection of viruses was performed in 22 µl-
volume reactions with the One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad, 
CA, USA), 1.0 µmol l-1 of each (virus-specific) forward and reverse primers, 0.2 µmol 
l-1 of probe (Table 1), and 5 µl of template RNA. Droplets were generated with 
Automated Droplet Generator (Bio-Rad), and the samples were then subjected to 
amplification in the following conditions: RT at 50°C for 60 min and initial activation at 
95°C for 10 min, followed by 43 cycles of 95°C for 30 s and 60°C for 60 s. 
Deactivation was done at 98°C for 10 min.  Results were analysed using the 
QX200™ Droplet Digital™ PCR System (Bio-Rad). Standard curves for the RT-
qPCR protocols were prepared from 10-fold serial dilutions of the standard samples. 
The RT-qPCR titers for the samples were obtained by plotting their Ct values against 
their corresponding standard curves. 
 
Statistical and mathematical analysis 
GraphPad Software (https://www.graphpad.com/quickcalcs/ttest1/) was used for the 
statistical pairwise t-test analyses of the results. P-values of <0.05 were considered 
statistically significant. When calculating log10-reductions, our principle was to 
compare every inactivated sample with the control (non-treated or treated), that gave 
the lowest titer.  Thus, RV was compared with controls that were not heat-
inactivated, but treated with PMA/PMAxx or nucleases. NoV was compared with 
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Results 
Thermal inactivation of the model viruses 
RV Wa was completely inactivated after heat treatment at 80°C for 5 min, when 
determined by the TCID50 method (data not shown). The heat-inactivated (80°C, 10 
min) fecal sample F_RV contained only destroyed remnants of viral particles in EM 
(data not shown).  The effect of the thermal inactivation on the RT-qPCR titers of Wa 
and F_RV (-0.07, and -0.26 log10 reductions, respectively) were negligible. In 
contrast, the titer of F_NoV decreased significantly, by 2.35 log10 gc (P <0.05; data 
not shown). The absolute titers are presented in table 2.  
Since the genome of F_NoV in our sample seemed to be heat-labile at 80°C, we 
tested if incubation at 37°C (the temperature used during nuclease treatments), 
would also alter its titer. However, no statistically different results were obtained 
between the samples incubated at 37°C and 6C° (the temperature used during PMA 
treatment) for 30 or 60 min (P >0.05; data not shown). Thus, identical pretreatment 
conditions were applied for RV and F-NoV. 
 
Effects of PMA/PMAxx treatments on the RT-qPCR titers of infectious and 
inactivated viruses 
Unbound PMA effectively inhibited the detection of free RV Wa nucleic acids by RT-
qPCR (P <0.05; data not shown). This effect was avoided by purification of the Wa 
RNA with the QiaQuick PCR Purification kit. Without photoactivation, PMA reduced 
the titer of the extracted, purified Wa RNA only negligibly (0.03 log10 gc; P >0.05), 
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Accordingly, when infectious or heat-inactivated RV were treated with PMA or 
PMAxx, but not subjected to photoactivation, their titers did not differ significantly 
from the controls (-0.23 – 0.09 log10 gc; P >0.05; data not shown).  
Unexpectedly, however, PMA treatment with photoactivation reduced the titers of 
infectious (no thermal treatment) Wa and F_RV by 0.73 and 1.65 log10 gc, 
respectively (P <0.05; Table 2, Fig. 1A, columns below x-axis). The same applied for 
PMAxx, with reductions of 1.63 and 2.02, respectively (P <0.05; Table 2, Fig. 1B). 
So, to verify the efficiency of PMA/PMAxx, we compared the results of the heat-
inactivated PMA/PMAxx-treated samples with the infectious, non-heat-inactivated 
PMA/PMAxx-treated controls (see the methods section for additional information). 
The log10 reductions of the heat-inactivated, PMA or PMAxx-treated Wa were 
modest, 0.18 and 0.21 log10 gc, respectively (P values for both <0.05; Fig. 1A and 
1B; columns on or above x-axis). PMA treatment hardly caused any titer-reduction 
for heat-inactivated F_RV (P = 0.5; Fig. 1A). However, the performance of PMAxx 
was better (0.86 log10 gc reduction; P <0.05; Fig.1B).  
Promisingly, and in contrast to the above-mentioned results with infectious RV and 
PMA/PMAxx, application of PMA or PMAxx into infectious F_NoV did not affect its 
titer (-0.05 to 0.02 log10 gc; P >0.05; Table 2), but thermal treatment did. So, we 
compared the heat-inactivated F_NoV that was PMA/PMAxx-treated with the heat-
inactivated non-PMA/PMAxx-treated counterparts (the controls that gave the lowest 
value). In addition to the F_NoV genome load decrease of 2.35 log10 by heat alone, 
pretreatment with PMA or PMAxx still resulted in further reductions of 0.79 and 0.84 
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Effects of nuclease treatments on the RT-qPCR titers of infectious and 
inactivated viruses 
Treatment of the extracted, non-purified or purified RV Wa RNA with 100 U of 
benzonase could render it non-detectable by RT-qPCR (4.48 - 4.72 log10 gc 
reduction; data not shown). When applied to the infectious Wa, benzonase 
pretreatment resulted in an unwanted decrease in the titer (0.76 log10 gc; P <0.05; 
Table 2, Fig. 1C), but, contrarily, did not decrease the titers of infectious F_RV and 
F_NoV (0.15 and 0.00 log10 gc, respectively (P >0.05; Table 2, Fig. 1C). Benzonase 
pretreatment reduced the titer of heat-inactivated Wa only by 0.38 log10 (P >0.05), 
but that of F_RV by 2.17 log10 gc (P <0.05) – the latter being the second-best value 
in the study – when compared to their infectious controls treated with benzonase 
(Fig. 1C). Benzonase pretreatment of the heat-inactivated F_NoV did not cause any 
further titer reduction (Fig. 1C).  
The titers of the infectious Wa, F_RV and F_NoV were somewhat reduced by the 
RNase treatment (0.88, 0.51 and 0.46 log10 gc, respectively; P values for all <0.05; 
Table 2, Fig. 1D). RNase worked well for the inactivated samples, since after heat-
treatment, the titers of Wa and F_RV were reduced by 1.66 and 2.77 log10 gc (P 
values for both <0.05), respectively, in comparison with their infectious controls 
treated with RNase (Fig. 1D). RNase treatment of the heat-inactivated F_NoV 
resulted in a further 0.80 log10-reduction, when compared to the inactivated F_NoV, 
not treated with RNase (P value <0.05; Fig. 1D). 
 
Discussion 
In this study, we evaluated the performance of different pretreatments in eliminating 
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reliable methods are urgently needed, especially for non-cultivable viruses 
(Ceuppens et al. 2014; Fuster et al. 2016). None of the pretreatments worked 
perfectly, since they were not able to render the inactivated virus samples negative 
in RT-qPCR. PMA/PMAxx pretreatments seemed to work to some extent for heat-
inactivated norovirus. Benzonase pretreatment worked well for F_RV (2.2 log10 gc 
reduction) and moderately for Wa, but not at all for NoV. The most promising of 
these pretreatments was with crude mixture of RNase that had some effect for both 
RV and NoV, and that gave the highest titer-reduction (almost 3 log10 for heat-
inactivated F_RV) of our study. 
We observed a difference in the thermal resistance at 80°C between dsRNA genome 
of RV and ssRNA genome of NoV GI (GI.6). Contrary to RV, a statistically significant 
(appr. 2-log) reduction in the F_NoV gc titer was noticed after heat treatment using 
RT-qPCR without any pretreatment. This finding is somewhat surprising, since other 
studies have reported zero to very minor decreases in the NoV genome after heating 
them at temperatures of 72-95°C for 5-15 min (Li et al. 2012; Escudero-Abarca et al. 
2014; Karim et al. 2015; Monteiro and Santos 2017). One exception is the study of 
Parshionikar et al. (2010) that shows an 11-fold decrease in Norwalk concentration 
after treatment at 37°C for 2 weeks by RT-qPCR alone. These discrepancies might 
be partly explained by that the other studies used more concentrated viruses during 
heating, while we wanted to perform our NoV tests in approximately the same 
concentration as the tests with RV, which was our primary target virus in this study.  
Individual qualitative and quantitative contents of fecal suspensions might have an 
effect as well. 
PMA treatment prior to RT-qPCR has been shown to be relatively reliable in 
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(Sánchez et al. 2012) and polioviruses (Parshionikar et al. 2010; Karim et al. 2015) 
have been treated. The results of NoV treatments with PMA are, however, 
controversial. Escudero-Abarca et al. (2014) determined the D value, which indicates 
the time required to destroy 90% of the microbe population for PMA-treated Snow 
Mountain virus (SMV; NoV GII) to be only 3.1 min at 80°C, suggesting good 
performance of PMA treatment for NoV.  
On the other hand, Parshionikar et al. (2010) reported that PMA treatment (100 µmol 
l-1) of heat-inactivated (72°C, about 5 min) NoV (103 gc ml-1) could render it non-
detectable by RT-PCR, although not with RT-qPCR. Karim et al. (2015) also 
reported the inefficiency of PMA to render NoV negative in RT-qPCR. Our results 
that were somewhat hampered by degradation of NoV genome during heat-
inactivation were in line with Karim et al. (2015), because PMA caused only less than 
a log10 reduction for F_NoV. PMAxx was found to function slightly better than PMA, 
but it was still not able to prevent all false-positive RT-qPCR signals. 
In our experiments, PMA and especially PMAxx treatment resulted in the genome 
titer reduction of the cell-grown Wa sample (0.73 log10 and 1.63 log10 gc, 
respectively), and also Coudray-Meunier et al. (2013) reported a reduction of 0.52 
log10 for RV with PMA. Cell-grown crude rotavirus samples contain always immature, 
non-infectious particles that have lost their outer capsids as well as viral components 
together with intact virions, as evidenced by EM (Settembre et al 2011). This could 
partially explain the reduction, since by PMA/PMAxx can enter partially damaged 
virus particles. To our knowledge, it has not been studied, whether the trypsin 
treatment of RV (that cleaves spike protein VP4 to subunits VP5* and VP8*), which 
is necessary for virus infectivity in cell culture, affects the accessibility of PMA into 
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Coudray-Meunier et al. (2013) reported that PMA treatment of the heat-inactivated 
RV Wa (68 or 80°C, 10 min) caused a 1.45 log10 reduction and Leifels et al. (2015) 
found that the PMA treatment reduced the titer of RV by 1.19 log10 (65°C, 10 min). In 
our hands, PMA/PMAxx treatment did not much affect the titer of the RV treated at 
80°C for 10 min (maximum decrease of 0.22 log10 gc). The discrepancies between 
the results of our and the abovementioned studies may be explained by the 
differences in the virus preparation, or in the methods used. However, the conclusion 
in both these studies was that viral targets influence the effectiveness and viruses 
have different inactivation mechanisms, which statements are in agreement with our 
results. 
To our knowledge, benzonase has not been used as an alternative for RNase 
before, so we have no reference to our results. Under the same thermal inactivation 
conditions, nearly similar titer reductions (2.17 and 2.77 log10 gc, respectively) were 
observed for fecal RV when it was treated with either benzonase or RNase prior to 
RT-qPCR. However, benzonase had little to no effect for the inactivated Wa and 
F_NoV. It is possible that there was something in the sample matrix of the cell-
cultured Wa that hindered the ability of benzonase to degrade free nucleic acids. 
While NoV results were obscured by the above-mentioned tremendous NoV genome 
degradation by heat alone, more research is clearly needed to reveal the applicability 
of benzonase pretreatment, when virus is inactivated with different processes (heat, 
UV, chlorine). However, by adjusting the inactivation conditions, and both benzonase 
and virus concentrations, this pretreatment may finally prove to be very practical.  
In our hands, RNase pretreatment performed well for RV (1.66 – 2.77 log10 
reductions for Wa and F_RV, respectively), when all three pretreatments were 
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results with RNase-treated RV. In a study of Coudray-Meunier et al. (2013) different 
pretreatments (PMA/EMA and surfactants) were used to develop a method to 
differentiate between infectious and inactivated RV particles by RT-qPCR. Given the 
importance of RV as a cause of waterborne outbreaks, RNase method should be 
further validated for RV, because it could prove to be very practical in situations, 
where water or food is suspected to be contaminated by feces. 
RNase pretreatment worked to some extent for NoV, causing a similar log10 
reduction as PMA/PMAxx pretreatments (0.80 log10 gc) without affecting infectious, 
non-heat-inactivated virus. Our NoV results are in line with those of several studies 
that have assessed the usability of RNase pretreatments to measure survival or 
persistence of NoV (Topping et al. 2009; Li et al. 2012; Escudero-Abarca et al. 2014; 
Rönnqvist et al. 2014; Manuel et al. 2017). For example, Li et al. (2012) reported a 
decrease of 1.15 log10 gc after heat-treatment of NoV GII.4 at 85°C for 2 min using 
RNAse ONE.  RNAse ONE treatment was also successfully used in the study of 
Escudero-Abarca et al. (2014) that determined the D value for the RNase treated 
SMV to be 3.9 min at 80°C. In contrast, in the study of Monteiro and Santos (2017), 
RNase A caused practically no decrease in the titer of heat-inactivated NoV GII.4. 
The discrepancies between these studies may result from numerous issues, e.g. the 
use of different NoV genotypes, virus concentrations, thermal treatments, type of 
RNase, and/or sample matrices.  
Almost all pre-RT-qPCR treatments seemed to be more effective in differentiating 
infectious from inactivated RV particles in the fecal sample, than in the cell-culture 
media. Indeed, it is important that pretreatments would work reliably for viruses in 
fecal matrix, since sewage of human origin is a common source for NoV and RV 
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conclusion, this study gives us more understanding about the performance of 
pretreatments in distinguishing infectious RV and NoV.  However, numerous data 
gaps have still to be filled, before the optimal pretreatments for particular viruses in 
various matrices, and after certain inactivation processes, can be established. 
 
Acknowledgements 
This study was partially funded by the European Community’s 7th framework 
research programme “Aquavalens” (Protecting the health of Europeans by improving 
methods for the detection of pathogens in drinking water and water used in food 
preparation; grant no. 311846), and the Walter Ehrström Foundation. We also want 
to thank Carl-Henrik von Bonsdorff for critical reading of this article, and for his 
valuable comments. 
The authors declare no conflict of interest. 
 
References 
Arnold, M., Patton, J.T. and McDonald, S.M. (2009) Culturing, storage, and quantification of rotaviruses. Curr Protoc Microbiol. 
Chapter 15: Unit 15C.3. doi: 10.1002/9780471729259.mc15c03s15. 
Azevedo, M.P., Vlasova, A.N. and Saif, L.J. (2013) Human rotavirus virus-like particle vaccines evaluated in a neonatal 
gnotobiotic pig model of human rotavirus disease. Expert Rev Vaccines 12, 169-181. 
Bae, J. and Schwab, K.J. (2007) Evaluation of murine norovirus, feline calicivirus, poliovirus, and MS2 as surrogates for human 
norovirus in a model of viral persistence in surface water and groundwater. Appl Environ Microbiol 74, 477-484.  
Ceuppens, S., Li, D., Uyttendaele, M., Renault, P., Ross, P., Van Ranst, M., Cocolin, L. and Donaghy, J. (2014) Molecular 
Methods in Food Safety Microbiology: Interpretation and Implications of Nucleic Acid Detection. Compr Rev Food Sci Food Saf 
13, 551-577. [Review] 
Cliver, D.O. (2009) Capsid and Infectivity in Virus Detection. Food Environ Virol 1, 123-128. 
Coudray-Meunier, C., Fraisse, A., Martin-Latil, S., Guillier, L. and Perelle, S. (2013) Discrimination of infectious hepatitis A virus 
and rotavirus by combining dyes and surfactants with RT-qPCR. BMC Microbiol 13, 216. 
da Silva, A.K., Le Saux, J.C., Parnaudeau, S., Pommepuy, M., Elimelech, M. and Le Guyader, F.S. (2007) Evaluation of 
removal of noroviruses during wastewater treatment, using real-time reverse transcription-PCR: different behaviors of 










This article is protected by copyright. All rights reserved. 
Diez-Valcarce, M., Kovac, K., Raspor, P., Rodriguez-Lazaro, D. and Hernandez, M. (2011) Virus Genome Quantification Does 
not Predict Norovirus Infectivity After Application of Food Inactivation Processing Technologies. Food Environl Virol 3, 141-146. 
Elizaquivel, P., Aznar, R. and Sanchez, G. (2014) Recent developments in the use of viability dyes and quantitative PCR in the 
food microbiology field. J Appl Microbiol 116, 1-13. [Review]  
Escudero-Abarca, B.I., Rawsthorne, H., Goulter, R.M., Suh, S.H. and Jaykus, L.A. (2014) Molecular methods used to estimate 
thermal inactivation of a prototype human norovirus: more heat resistant than previously believed? Food Microbiol 41, 91-5.  
Espinosa, A.C., Mazari-Hiriart, M., Espinosa, R., Maruri-Avidal, L., Méndez, E. and Arias, C.F. (2008) Infectivity and genome 
persistence of rotavirus and astrovirus in groundwater and surface water. Water Res 42, 2618-2628. 
Fuster, N., Pinto, R.M., Fuentes, C., Beguiristain, N., Bosch, A. and Guix, S. (2016) Propidium monoazide RTqPCR assays for 
the assessment of hepatitis A inactivation and for a better estimation of the health risk of contaminated waters. Water Res 101, 
226-232. 
Hoehne, M. and Schreier, E. (2006) Detection of Norovirus genogroup I and II by multiplex real-time RT- PCR using a 3'-minor 
groove binder-DNA probe. BMC Infect Dis 6, 69. 
Kantala, T., Maunula, L., von Bonsdorff, C.H., Peltomaa, J. and Lappalainen, M. (2009) Hepatitis E virus in patients with 
unexplained hepatitis in Finland. J Clin Virol 45, 109-113. 
Karim, M.R., Fout, G.S., Johnson, C.H., White, K.M. and Parshionikar, S.U. (2015) Propidium monoazide reverse transcriptase 
PCR and RT-qPCR for detecting infectious enterovirus and norovirus. J Virol Methods 219, 51-61. 
Kim, S.Y. and Ko, G. (2012) Using propidium monoazide to distinguish between viable and nonviable bacteria, MS2 and murine 
norovirus. Lett Appl Microbiol 55, 182-188. 
Kiulia, N.M., Netshikweta, R., Page, N.A., Van Zyl, W.B., Kiraithe, M.M., Nyachieo, A., Mwenda, J.M. and Taylor, M.B. (2010) 
The detection of enteric viruses in selected urban and rural river water and sewage in Kenya, with special reference to 
rotaviruses. J Appl Microbiol 109, 818-828. 
Lamhoujeb, S., Fliss, I., Ngazoa, S.E. and Jean, J. (2008) Evaluation of the persistence of infectious human noroviruses on 
food surfaces by using real-time nucleic acid sequence-based amplification. Appl Environ Microbiol 74, 3349-3355. 
Leifels, M., Jurzik, L., Wilhelm, M. and Hamza, I.A. (2015) Use of ethidium monoazide and propidium monoazide to determine 
viral infectivity upon inactivation by heat, UV- exposure and chlorine. Int J Hyg Environ Health 218, 686-693. 
Li, D., Baert, L., Van Coillie, E. and Uyttendaele, M. (2011) Critical studies on binding-based RT-PCR detection of infectious 
Noroviruses. J Virol Methods 177, 153-159. 
Li, D., Baert, L., Xia, M., Zhong, W., Van Coillie, E., Jiang, X. and Uyttendaele M. (2012) Evaluation of methods measuring the 
capsid integrity and/or functions of noroviruses by heat inactivation. J Virol Methods 181, 1-5.  
Lodder, W.J. and de Roda Husman, A.M. (2005) Presence of noroviruses and other enteric viruses in sewage and surface 
waters in The Netherlands. Appl Environ Microbiol 71, 1453-1461. 
Manuel, C.S., Moore, M.D. and Jaykus, L.A. (2017) Efficacy of a disinfectant containing silver dihydrogen citrate against GI.6 
and GII.4 human norovirus. J Appl Microbiol 122, 78-86. 
Miller, MD., Tanner, J., Alpaugh, M., Benedik, M.J. and Krause, K.L. (1994) 2.1 Angstrom structure of Serratia endonuclease 
suggests a mechanism for binding to double-stranded DNA. Nat Struct Biol 1, 461-468. 
Monteiro, S. and Santos, R. (2017) Enzymatic and viability RT-qPCR assays for evaluation of enterovirus, hepatitis A virus and 










This article is protected by copyright. All rights reserved. 
Nuanualsuwan, S. and Cliver, D.O. (2002) Pretreatment to avoid positive RT-PCR results with inactivated viruses. J Virol 
Methods 104, 217-225. 
Oristo, S., Rönnqvist, M., Aho, M., Sovijarvi, A., Hannila-Handelberg, T., Horman, A., Nikkari, S., Kinnunen, P.M. and Maunula, 
L. (2017) Contamination by Norovirus and Adenovirus on Environmental Surfaces and in Hands of Conscripts in Two Finnish 
Garrisons. Food Environ Virol 9, 62-71. 
Parshionikar, S., Laseke, I. and Fout, G.S. (2010) Use of propidium monoazide in reverse transcriptase PCR to distinguish 
between infectious and noninfectious enteric viruses in water samples. Appl Environ Microbiol 76, 4318-4326. 
Pires, S.M., Fischer-Walker, C.L., Lanata, C.F., Devleesschauwer, B., Hall, A.J., Kirk, M.D., Duarte, A.S., Black, R.E. and 
Angulo, F.J. (2015) Aetiology-Specific Estimates of the Global and Regional Incidence and Mortality of Diarrhoeal Diseases 
Commonly Transmitted through Food. PLoS One 10, e0142927. 
Rönnqvist, M., Mikkelä, A., Tuominen, P., Salo, S. and Maunula, L. (2014) Ultraviolet Light Inactivation of Murine Norovirus and 
Human Norovirus GII: PCR May Overestimate the Persistence of Noroviruses Even When Combined with Pre-PCR 
Treatments. Food Environ Virol 6, 48-57. 
Sánchez, G., Elizaquivel, P. and Aznar, R. (2012) Discrimination of infectious hepatitis A viruses by propidium monoazide real-
time RT-PCR. Food Environ Virol 4, 21-25. 
Settembre, E.C., Chen, J.Z., Dormitzer, P.R., Grigorieff, N. and Harrison, S.C. (2011) Atomic model of an infectious rotavirus 
particle. EMBO J 30, 408-416. 
Svraka, S., Duizer, E., Vennema, H., de Bruin, E., van der Veer, B., Dorresteijn, B. and Koopmans, M. (2007) Etiological role of 
viruses in outbreaks of acute gastroenteritis in The Netherlands from 1994 through 2005. J Clin Microbiol 45, 1389-1394. 
Tan, M. and Jiang X. (2014) Vaccine against norovirus. Hum Vaccin Immunother 10, 1449-56. [Review] 
Tate, J.E., Burton, A.H., Boschi-Pinto, C., Steele, A.D., Duque, J., Parashar, U.D. and Network, W.H.-c.G.R.S. (2012) 2008 
estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal 
rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 12, 136-141. 
Tate, J.E. and Parashar, U.D. (2014) Rotavirus vaccines in routine use. Clin Infect Dis 59, 1291-1301. 
Tate, J.E., Burton, A.H., Boschi-Pinto, C. and Parashar, U.D. (2016) Global, Regional, and National Estimates of Rotavirus 
Mortality in Children <5 Years of Age, 2000-2013. Clin Infect Dis 62, S96-S105.  
Topping, J.R., Schnerr, H., Haines, J., Scott, M., Carter, M.J., Willcocks, M.M., Bellamy, K., Brown, D.W., Gray, J.J., Gallimore, 
C.I. and Knight, A.I. (2009) Temperature inactivation of Feline calicivirus vaccine strain FCV F-9 in comparison with human 
noroviruses using an RNA exposure assay and reverse transcribed quantitative real-time polymerase chain reaction–A novel 
method for predicting virus infectivity. J Virol Methods 156, 89-95. 
Zeng, S.Q., Halkosalo, A., Salminen, M., Szakal, E.D., Puustinen, L. and Vesikari, T. (2008) One-step quantitative RT-PCR for 
the detection of rotavirus in acute gastroenteritis. J Virol Methods 153, 238-240. 
 
Figure legend 
Figure 1. The log10 genome copy reductions of rotaviruses (cell-cultured Wa strain 
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benzonase (C) or RNase (D) with or without heat-inactivation (80˚C, 10 min).  
Infectious, pretreated rotavirus (RV) was compared with infectious RV , with heat-
inactivated RV  or with heat-inactivated, pretreated RV . In case of norovirus, 
heat-inactivated, pretreated F_NoV was compared with infectious F_NoV , 
infectious, pretreated F_NoV  or with heat-inactivated, pretreated F_NoV . (See 
methods for details). 
 
 
Table 1. The primers and probes used in the RT-qPCR assays in this study 





RV Wa and 
F_RV* 
Z_RV_F ACCATCTACACATGACCCTCTATGAG 963 – 988
 
†   87 Modified from 
Zeng et al. 2008 
 Z_RV_R GGTCACATAACGCCCCTATAGC 1028 – 1049† Zeng et al. 2008 
F_NoV QNIF4 CGCTGGATGCGNTTCCAT 
 
5291 – 5308 ‡ 86 da Silva et al. 
2007 
 NVLCR1 CCTTAGACGCCATCATCATTTAC 5354 – 5376
 
‡ Svraka et al. 2007 
 TM9 FAM-TGGACAGGAGATCGC-MGB-
NFQ 




 RV Wa: Cell-cultured rotavirus Wa strain; F_RV: RV-positive fecal sample, genotype GI.P[8], NoV GI: Norovirus genogroup 
I, fecal sample positive for NoV GI.Pb – GI.6. 
†
 
 Positions based on Human rotavirus NSP3 (NS34) mRNA region (GenBank accession no. X81436) 
‡
 
 Positions based on complete NoV GI genome (GenBank accession no. M87661) 
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Table 2. The log10 genome copy (gc) titers of cell-cultured rotavirus strain Wa, rotavirus G1P[8] positive fecal sample (F_RV), 
and norovirus GI.Pb-GI.6 positive fecal sample (F_NoV), with or without heat-inactivation (80˚C, 10 min) and pretreatment with 
either PMA (100 µmol l
-1
), PMAxx (100 µmol l
-1
), benzonase (100 U) or RNase (4 U), as calculated with RT-qPCR.  (Mean ± 
standard deviation).  












Wa 5.38 ± 0.16 4.65 ± 0.10 5.49 ± 0.10 4.47 ± 0.05 
 F_RV 6.09 ± 0.06 4.44 ± 0.24 6.30 ± 0.22 4.56 ± 0.24 
 F_NoV 5.82 ± 0.39 5.87 ± 0.43 3.38 ± 0.21 2.59 ± 0.10 
      
PMAxx  
 
Wa 5.38 ± 0.16 3.75 ± 0.11 5.49 ± 0.10 3.54 ± 0.07 
 F_RV 6.16 ± 0.09 4.14 ± 0.47 6.43 ± 0.35 3.28 ± 0.41 
 F_NoV 5.82 ± 0.39 5.80 ± 0.46 3.38 ± 0.21 2.54 ± 0.10 
      
Benzonase  Wa 5.44 ± 0.21/ 
5.24 ± 0.08*  
4.48 ± 0.00 5.44 ± 0.12 4.29 ± 0.21 
 F_RV 5.98 ± 0.22/ 
5.86 ± 0.21* 
5.71 ± 0.28 6.19 ± 0.46 3.26 ± 0.40 
 F_NoV 5.40 ± 0.12 5.39 ± 0.13 3.10 ± 0.13 3.16 ± 0.08 
      
RNase Wa 5.42 ± 0.19/ 
5.27 ± 0.08* 
4.39 ± 0.08 5.46 ± 0.11 2.67 ± 0.12 
 F_RV 5.98 ± 0.22/ 
5.86 ± 0.22* 
5.35 ± 0.19 6.06 ± 0.30 2.52 ± 0.39 
 F_NoV 5.33 ± 0.04 4.87 ± 0.30  3.10 ± 0.16 2.30 ± 0.36 
      
* The average log10 genome copy (gc) titers of controls that were included in the RT-qPCR tests of the 
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